SlideShare a Scribd company logo
1 of 16
Download to read offline
Editorial Slides
VP Watch –July 24, 2002 - Volume 2, Issue 29
AHA 2002 Guideline; 1997 or 2002?
Major Eras in Atherosclerosis
Cholesterol
Non-Lipid Risk Factors
Immune Disorder
1950 1970 2002
(Inflammation Era)
Diet
Era 1
Era 2
Era 3
 The landmark Seven Countries Study established the
“diet-heart cholesterol theory”.
 This classic diet-heart cholesterol theory is supported
by results from ecological analyses, prospective studies,
animal experiments, clinical observations, controlled
trials, biochemical and nutritional studies.
 Since 1968 extensive epidemiologic and clinical studies
have identified several factors that increase the risk of
CHD and MI, with effects not necessarily involving
serum cholesterol and lipids.
 Traditional Risk Factors (Era 1)
 Sex
 Age
 Hypercholesterolemia
 Smoking
 Hypertension
 Diabetes
 Physical Activity
 Family History
 Non-Traditional Risk Factors (Era 2)
 Fibrinogen
 Homocysteine
 White Blood Cell Count
 LP(a)
 ApoB/ApoA
 Heart Rate
 Socioeconomic Status
 Stress
 Type A Personality
 Body Mass Index
 …
 Novel Risk Factors (Era 3)
 CRP
 IL-6
 CD40/CD40L
 Pathogen burden
 HSP-60
 …
• “Risk Calculators” are only based on
traditional risk factors:
• Framingham Risk Assessment
• Sheffield Risk Assessment
• MONICA
• Dundee
• RisCard
 The Framingham model uses age, sex, LDL or
total cholesterol, HDL, systolic and diastolic
blood pressure, the presence or absence of
diabetes mellitus, and smoking status to predict
the 10-year risk of CHD events. 10
• Sheffield table for primary prevention of
coronary heart disease shows serum
cholesterol concentration conferring an
estimated risk of coronary events of 3.0% per
year. 5
• National Heart, Lung, and Blood Institute
presented the risk assessment tool using
information from the Framingham Heart Study to
predict a person’s chance of having a heart
attack in the next 10 years.
 However, numerous studies have accumulated
abundance of data indicating significance of
non-traditional and emerging risk factors like
CRP, fibrinogen, homocysteine, sLDL, and
calcium score.
 As reported in VP Watch of this
week, Pearson et al. in 2002 update of AHA
guidelines for primary prevention of
cardiovascular disease and stroke integrated
other guidelines and consensus statements
developed since the initial Guide’s approval.11
 This Guide is intended to assist primary care
providers in their assessment, management,
and follow-up of patients who may be at risk
for but who have not yet manifested
cardiovascular disease. 11
 The aspirin guidelines recommended in
this update agree with the Task Force
Report in the use of aspirin in persons at
high coronary and stroke risk but uses a
10% risk per 10 years rather than >6%
risk over 10 years. 11
 This change slightly restricts use of
aspirin due to its potential adverse
effects.
Conclusion:
 Despite the fast growing body of
evidence for significance of non-
traditional risk factors, the AHA 2002
Guideline calls screening tests for occult
atherosclerosis based on non-traditional
risk factors (CRP…) confined in the
research arena, except ankle-brachial
blood pressure index.
Conclusion:
 The Guideline also does not appreciate
non-lipid lowering effects of statins and
emphasizes that controversial
interventions, such as very low-fat diets,
dietary supplements, and potentially
cardioprotective drugs other than aspirin
require additional investigation in well-
designed clinical trials in persons without
established cardiovascular disease.
Questions:
• Should CRP be added to the package of
screening tests for CVD primary
prevention in asymptomatic populations?
• How about for secondary prevention?
• Should coronary calcium score be
considered as an independent risk factor?
Questions:
• Is annual risk calculated based on population studies a
reasonable basis for individual treatment?
• Is 2% annual risk a proper cut point for intervention?
• Do we need multiple risk cut points for different types
of interventions e.g. life-style, conventional drug
therapy, aggressive drug therapy, invasive treatment,
etc?
• Besides aspirin should we add other drug therapies
(such as statins) to the primary intervention therapy?
1) Grundy SM, Balady GJ, Criqui MH, et al. Guide to primary prevention of cardiovascular diseases: a statement for healthcare
professionals from the Task Force on Risk Reduction. American Heart Association Science Advisory and Coordinating Committee.
Circulation. 1997; 95: 2329–2331
2) National Cholesterol Education Program: Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel II). Circulation.. 1994;89:1333-1445
3) Diane L. Tribble; Antioxidant Consumption and Risk of Coronary Heart Disease: Emphasis on Vitamin C, Vitamin E, and ß-Carotene : A
Statement for Healthcare Professionals From the American Heart Association; Circulation 1999 99: 591 - 595.
4) Rosamond WD, Folsom AR, Chambless LE, Wang CH; ARIC Investigators. Atherosclerosis Risk in Communities.:Coronary heart
disease trends in four United States communities. The Atherosclerosis Risk in Communities (ARIC) study 1987-1996. Int J Epidemiol.
2001 Oct;30 Suppl 1:S17-22.
5) Wallis EJ, Ramsay LE, Ul Haq I, Ghahramani P, Jackson PR, Rowland-Yeo K, Yeo WW: Coronary and cardiovascular risk estimation
for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population.
6) Haq IU, Jackson PR, Yeo WW, Ramsay LE.: Sheffield risk and treatment table for cholesterol lowering for primary prevention of
coronary heart disease. Lancet 1995 Dec 2;346(8988):1467-71
7) Luc G, Bard JM, Ferrieres J, Evans A, Amouyel P, Arveiler D, Fruchart JC, Ducimetiere P.:Value of HDL Cholesterol, Apolipoprotein A-
I, Lipoprotein A-I, and Lipoprotein A-I/A-II in Prediction of Coronary Heart Disease: The PRIME Study. Arterioscler Thromb Vasc Biol
2002 Jul 1;22(7):1155-61
8) Nallamothu BK, Fendrick AM, Omenn GS.Homocyst(e)ine and Coronary Heart Disease: Pharmacoeconomic Support for Interventions
to Lower Hyperhomocyst(e)inaemia.Pharmacoeconomics 2002;20(7):429-42
9) Gerber Y, Goldbourt U, Cohen H, Harats D.:Association Between Serum Apolipoprotein C(II) Concentration and Coronary
Heart Disease. Prev Med 2002 Jul;35(1):42-7
10) Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-
47.
11) Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong
Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF Jr, Smith SC Jr, Stone NJ, Taubert KA. : AHA Guidelines for Primary
Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult
Patients Without Coronary or Other Atherosclerotic Vascular Diseases. : Circulation. 2002 Jul 16;106(3):388-91.
References

More Related Content

What's hot

Cardiovascular diseases traditional_and_non-tradit
Cardiovascular diseases traditional_and_non-traditCardiovascular diseases traditional_and_non-tradit
Cardiovascular diseases traditional_and_non-traditArhamSheikh1
 
Guidelines For Assessment Of C Visk In Rsymptomatic Adults
Guidelines For Assessment Of C Visk In Rsymptomatic AdultsGuidelines For Assessment Of C Visk In Rsymptomatic Adults
Guidelines For Assessment Of C Visk In Rsymptomatic AdultsJuan Menendez
 
International Society of Hypertension 2020 guidlines
International Society of Hypertension 2020 guidlinesInternational Society of Hypertension 2020 guidlines
International Society of Hypertension 2020 guidlinesJAFAR ALSAID
 
Fatty Acids and their role in Cardiometabolic Health
Fatty Acids and their role in Cardiometabolic HealthFatty Acids and their role in Cardiometabolic Health
Fatty Acids and their role in Cardiometabolic HealthArindam Pande
 
Cardiovascular disease Cardiovascular Disease in Rheumatoid Arthritis: A Syst...
Cardiovascular disease Cardiovascular Disease in Rheumatoid Arthritis: A Syst...Cardiovascular disease Cardiovascular Disease in Rheumatoid Arthritis: A Syst...
Cardiovascular disease Cardiovascular Disease in Rheumatoid Arthritis: A Syst...Juan Sebastian Espinosa-Serna
 
Chronic obstructive pulmonary diseases presentation at Hackensack Meridian he...
Chronic obstructive pulmonary diseases presentation at Hackensack Meridian he...Chronic obstructive pulmonary diseases presentation at Hackensack Meridian he...
Chronic obstructive pulmonary diseases presentation at Hackensack Meridian he...Raghunath Ramanarasimhaiah MS, MD
 
"Obesity paradox" and Cardiovascular Disease: Myth or a Better Clinical Outcome?
"Obesity paradox" and Cardiovascular Disease: Myth or a Better Clinical Outcome?"Obesity paradox" and Cardiovascular Disease: Myth or a Better Clinical Outcome?
"Obesity paradox" and Cardiovascular Disease: Myth or a Better Clinical Outcome?science journals
 
Risk factors of Acute Coronary Syndrome at Prince Ali Bin Alhussein hospital
Risk factors of Acute Coronary Syndrome at Prince Ali Bin Alhussein hospitalRisk factors of Acute Coronary Syndrome at Prince Ali Bin Alhussein hospital
Risk factors of Acute Coronary Syndrome at Prince Ali Bin Alhussein hospitalMinistry of Health
 
Hf eugene braunwald 2013
Hf  eugene braunwald 2013Hf  eugene braunwald 2013
Hf eugene braunwald 2013drucsamal
 
Epidemiology of Cardiovascular Diseases
Epidemiology of Cardiovascular DiseasesEpidemiology of Cardiovascular Diseases
Epidemiology of Cardiovascular DiseasesSarinkumar P S
 
The effects of_the_mediterranean_diet_on_chronic_d
The effects of_the_mediterranean_diet_on_chronic_dThe effects of_the_mediterranean_diet_on_chronic_d
The effects of_the_mediterranean_diet_on_chronic_dArnon Ngoenyuang
 
Heart Disease Analysis System
Heart Disease Analysis SystemHeart Disease Analysis System
Heart Disease Analysis Systemijtsrd
 
Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...
Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...
Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...LupusNY
 
What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“Arindam Pande
 
Coronary heart disease
Coronary heart diseaseCoronary heart disease
Coronary heart diseasedrsanjeev15
 

What's hot (19)

Cardiovascular diseases traditional_and_non-tradit
Cardiovascular diseases traditional_and_non-traditCardiovascular diseases traditional_and_non-tradit
Cardiovascular diseases traditional_and_non-tradit
 
Guidelines For Assessment Of C Visk In Rsymptomatic Adults
Guidelines For Assessment Of C Visk In Rsymptomatic AdultsGuidelines For Assessment Of C Visk In Rsymptomatic Adults
Guidelines For Assessment Of C Visk In Rsymptomatic Adults
 
Herrick et al _JCDR 2014
Herrick et al _JCDR 2014Herrick et al _JCDR 2014
Herrick et al _JCDR 2014
 
International Society of Hypertension 2020 guidlines
International Society of Hypertension 2020 guidlinesInternational Society of Hypertension 2020 guidlines
International Society of Hypertension 2020 guidlines
 
Fatty Acids and their role in Cardiometabolic Health
Fatty Acids and their role in Cardiometabolic HealthFatty Acids and their role in Cardiometabolic Health
Fatty Acids and their role in Cardiometabolic Health
 
Osborn - Lipids 2019 cholesterol guidelines
Osborn - Lipids 2019 cholesterol guidelinesOsborn - Lipids 2019 cholesterol guidelines
Osborn - Lipids 2019 cholesterol guidelines
 
Cardiovascular disease Cardiovascular Disease in Rheumatoid Arthritis: A Syst...
Cardiovascular disease Cardiovascular Disease in Rheumatoid Arthritis: A Syst...Cardiovascular disease Cardiovascular Disease in Rheumatoid Arthritis: A Syst...
Cardiovascular disease Cardiovascular Disease in Rheumatoid Arthritis: A Syst...
 
Chronic obstructive pulmonary diseases presentation at Hackensack Meridian he...
Chronic obstructive pulmonary diseases presentation at Hackensack Meridian he...Chronic obstructive pulmonary diseases presentation at Hackensack Meridian he...
Chronic obstructive pulmonary diseases presentation at Hackensack Meridian he...
 
"Obesity paradox" and Cardiovascular Disease: Myth or a Better Clinical Outcome?
"Obesity paradox" and Cardiovascular Disease: Myth or a Better Clinical Outcome?"Obesity paradox" and Cardiovascular Disease: Myth or a Better Clinical Outcome?
"Obesity paradox" and Cardiovascular Disease: Myth or a Better Clinical Outcome?
 
International Journal of Cardiovascular Diseases & Diagnosis
International Journal of Cardiovascular Diseases & DiagnosisInternational Journal of Cardiovascular Diseases & Diagnosis
International Journal of Cardiovascular Diseases & Diagnosis
 
Risk factors of Acute Coronary Syndrome at Prince Ali Bin Alhussein hospital
Risk factors of Acute Coronary Syndrome at Prince Ali Bin Alhussein hospitalRisk factors of Acute Coronary Syndrome at Prince Ali Bin Alhussein hospital
Risk factors of Acute Coronary Syndrome at Prince Ali Bin Alhussein hospital
 
Hf eugene braunwald 2013
Hf  eugene braunwald 2013Hf  eugene braunwald 2013
Hf eugene braunwald 2013
 
Epidemiology of Cardiovascular Diseases
Epidemiology of Cardiovascular DiseasesEpidemiology of Cardiovascular Diseases
Epidemiology of Cardiovascular Diseases
 
The effects of_the_mediterranean_diet_on_chronic_d
The effects of_the_mediterranean_diet_on_chronic_dThe effects of_the_mediterranean_diet_on_chronic_d
The effects of_the_mediterranean_diet_on_chronic_d
 
Hypokalemia in Emergency Medicine
Hypokalemia in Emergency MedicineHypokalemia in Emergency Medicine
Hypokalemia in Emergency Medicine
 
Heart Disease Analysis System
Heart Disease Analysis SystemHeart Disease Analysis System
Heart Disease Analysis System
 
Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...
Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...
Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...
 
What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“
 
Coronary heart disease
Coronary heart diseaseCoronary heart disease
Coronary heart disease
 

Viewers also liked

137 inflammatory cells in non ruptured atherosclerotic plaques
137 inflammatory cells in non ruptured atherosclerotic plaques137 inflammatory cells in non ruptured atherosclerotic plaques
137 inflammatory cells in non ruptured atherosclerotic plaquesSHAPE Society
 
078 infrared spectroscopy of atherosclerotic plaque
078 infrared spectroscopy of atherosclerotic plaque078 infrared spectroscopy of atherosclerotic plaque
078 infrared spectroscopy of atherosclerotic plaqueSHAPE Society
 
146 animal models of vulnerable plaque
146 animal models of vulnerable plaque146 animal models of vulnerable plaque
146 animal models of vulnerable plaqueSHAPE Society
 
118 cell culture study
118 cell culture study118 cell culture study
118 cell culture studySHAPE Society
 
505 definitions of arterial remodeling in post mortem and intravascular ultra...
505 definitions of arterial remodeling in post mortem and intravascular ultra...505 definitions of arterial remodeling in post mortem and intravascular ultra...
505 definitions of arterial remodeling in post mortem and intravascular ultra...SHAPE Society
 
151 performance of a localized fiber optic
151 performance of a localized fiber optic151 performance of a localized fiber optic
151 performance of a localized fiber opticSHAPE Society
 
222 animal models of heart attack
222 animal models of heart attack222 animal models of heart attack
222 animal models of heart attackSHAPE Society
 
239 coronary artery calcium
239 coronary artery calcium239 coronary artery calcium
239 coronary artery calciumSHAPE Society
 
107 spio in apo e mouse
107 spio in apo e mouse107 spio in apo e mouse
107 spio in apo e mouseSHAPE Society
 
256 spatial encoding part 2
256 spatial encoding part 2256 spatial encoding part 2
256 spatial encoding part 2SHAPE Society
 
236 complement inhibitor
236 complement inhibitor236 complement inhibitor
236 complement inhibitorSHAPE Society
 
197 reducing atherosclerosis in mice
197 reducing atherosclerosis in mice197 reducing atherosclerosis in mice
197 reducing atherosclerosis in miceSHAPE Society
 
199 plaque severity and coronary occlusion
199 plaque severity and coronary occlusion199 plaque severity and coronary occlusion
199 plaque severity and coronary occlusionSHAPE Society
 
Acc 2002 mehran for print
Acc 2002  mehran for printAcc 2002  mehran for print
Acc 2002 mehran for printSHAPE Society
 
128 apo e deficient mice
128 apo e deficient mice128 apo e deficient mice
128 apo e deficient miceSHAPE Society
 

Viewers also liked (20)

137 inflammatory cells in non ruptured atherosclerotic plaques
137 inflammatory cells in non ruptured atherosclerotic plaques137 inflammatory cells in non ruptured atherosclerotic plaques
137 inflammatory cells in non ruptured atherosclerotic plaques
 
078 infrared spectroscopy of atherosclerotic plaque
078 infrared spectroscopy of atherosclerotic plaque078 infrared spectroscopy of atherosclerotic plaque
078 infrared spectroscopy of atherosclerotic plaque
 
146 animal models of vulnerable plaque
146 animal models of vulnerable plaque146 animal models of vulnerable plaque
146 animal models of vulnerable plaque
 
118 cell culture study
118 cell culture study118 cell culture study
118 cell culture study
 
036 dogs heart
036 dogs heart036 dogs heart
036 dogs heart
 
5
55
5
 
505 definitions of arterial remodeling in post mortem and intravascular ultra...
505 definitions of arterial remodeling in post mortem and intravascular ultra...505 definitions of arterial remodeling in post mortem and intravascular ultra...
505 definitions of arterial remodeling in post mortem and intravascular ultra...
 
189 hsp 65
189 hsp 65189 hsp 65
189 hsp 65
 
103100
103100103100
103100
 
151 performance of a localized fiber optic
151 performance of a localized fiber optic151 performance of a localized fiber optic
151 performance of a localized fiber optic
 
222 animal models of heart attack
222 animal models of heart attack222 animal models of heart attack
222 animal models of heart attack
 
239 coronary artery calcium
239 coronary artery calcium239 coronary artery calcium
239 coronary artery calcium
 
107 spio in apo e mouse
107 spio in apo e mouse107 spio in apo e mouse
107 spio in apo e mouse
 
256 spatial encoding part 2
256 spatial encoding part 2256 spatial encoding part 2
256 spatial encoding part 2
 
236 complement inhibitor
236 complement inhibitor236 complement inhibitor
236 complement inhibitor
 
197 reducing atherosclerosis in mice
197 reducing atherosclerosis in mice197 reducing atherosclerosis in mice
197 reducing atherosclerosis in mice
 
199 plaque severity and coronary occlusion
199 plaque severity and coronary occlusion199 plaque severity and coronary occlusion
199 plaque severity and coronary occlusion
 
Acc 2002 mehran for print
Acc 2002  mehran for printAcc 2002  mehran for print
Acc 2002 mehran for print
 
Ac cculprit
Ac cculpritAc cculprit
Ac cculprit
 
128 apo e deficient mice
128 apo e deficient mice128 apo e deficient mice
128 apo e deficient mice
 

Similar to 234 aha 2002 guideline, 1997 or 2002

Diagnosis of Early Risks, Management of Risks, and Reduction of Vascular Dise...
Diagnosis of Early Risks, Management of Risks, and Reduction of Vascular Dise...Diagnosis of Early Risks, Management of Risks, and Reduction of Vascular Dise...
Diagnosis of Early Risks, Management of Risks, and Reduction of Vascular Dise...asclepiuspdfs
 
8 8 16_gerber_savagian_poster_final
8 8 16_gerber_savagian_poster_final8 8 16_gerber_savagian_poster_final
8 8 16_gerber_savagian_poster_finalIvor Cummins
 
Risk assessment for cardiovascular disease prevention
Risk assessment for cardiovascular disease preventionRisk assessment for cardiovascular disease prevention
Risk assessment for cardiovascular disease preventionMohamed Badheeb
 
Consenso en prevención de enf cardiovascular en diabéticos
Consenso en   prevención de enf cardiovascular en diabéticosConsenso en   prevención de enf cardiovascular en diabéticos
Consenso en prevención de enf cardiovascular en diabéticosJose Mejias Melendez
 
Consenso en prevención de enf cardiovascular en diabéticos
Consenso en   prevención de enf cardiovascular en diabéticosConsenso en   prevención de enf cardiovascular en diabéticos
Consenso en prevención de enf cardiovascular en diabéticosJose Mejias Melendez
 
Consenso en prevención de enf cardiovascular en diabéticos
Consenso en   prevención de enf cardiovascular en diabéticosConsenso en   prevención de enf cardiovascular en diabéticos
Consenso en prevención de enf cardiovascular en diabéticosJose Mejias Melendez
 
Consenso en prevención de enf cardiovascular en diabéticos
Consenso en   prevención de enf cardiovascular en diabéticosConsenso en   prevención de enf cardiovascular en diabéticos
Consenso en prevención de enf cardiovascular en diabéticosJose Mejias Melendez
 
Consenso en prevención de enf cardiovascular en diabéticos
Consenso en   prevención de enf cardiovascular en diabéticosConsenso en   prevención de enf cardiovascular en diabéticos
Consenso en prevención de enf cardiovascular en diabéticosJose Mejias Melendez
 
Consenso en prevención de enf cardiovascular en diabéticos (1)
Consenso en   prevención de enf cardiovascular en diabéticos (1)Consenso en   prevención de enf cardiovascular en diabéticos (1)
Consenso en prevención de enf cardiovascular en diabéticos (1)Jose Mejias Melendez
 
Consenso en prevención de enf cardiovascular en diabéticos
Consenso en   prevención de enf cardiovascular en diabéticosConsenso en   prevención de enf cardiovascular en diabéticos
Consenso en prevención de enf cardiovascular en diabéticosJose Mejias Melendez
 
Consenso en prevención de enf cardiovascular en diabéticos (1)
Consenso en   prevención de enf cardiovascular en diabéticos (1)Consenso en   prevención de enf cardiovascular en diabéticos (1)
Consenso en prevención de enf cardiovascular en diabéticos (1)Jose Mejias Melendez
 
Consenso en prevención de enf cardiovascular en diabéticos
Consenso en   prevención de enf cardiovascular en diabéticosConsenso en   prevención de enf cardiovascular en diabéticos
Consenso en prevención de enf cardiovascular en diabéticosJose Mejias Melendez
 
2014 Report: Medicines in Development for Older Americans
2014 Report: Medicines in Development for Older Americans2014 Report: Medicines in Development for Older Americans
2014 Report: Medicines in Development for Older AmericansPhRMA
 
New Year, New You: Give 2012 a Heart Healthy Start!
New Year, New You: Give 2012 a Heart Healthy Start!New Year, New You: Give 2012 a Heart Healthy Start!
New Year, New You: Give 2012 a Heart Healthy Start!Regina Druz, MD, FACC
 
259 crp as a risk factor
259 crp as a risk factor259 crp as a risk factor
259 crp as a risk factorSHAPE Society
 
07 exemplo de metanálise
07   exemplo de metanálise07   exemplo de metanálise
07 exemplo de metanálisegisa_legal
 
Polypill for primary and secondary preventions of cardiovascular
Polypill for primary and secondary preventions of cardiovascularPolypill for primary and secondary preventions of cardiovascular
Polypill for primary and secondary preventions of cardiovascularBhaswat Chakraborty
 

Similar to 234 aha 2002 guideline, 1997 or 2002 (20)

Diagnosis of Early Risks, Management of Risks, and Reduction of Vascular Dise...
Diagnosis of Early Risks, Management of Risks, and Reduction of Vascular Dise...Diagnosis of Early Risks, Management of Risks, and Reduction of Vascular Dise...
Diagnosis of Early Risks, Management of Risks, and Reduction of Vascular Dise...
 
Aha guidelines for primary prevention of cardiovascular disease and stroke
Aha guidelines for primary prevention of cardiovascular disease and strokeAha guidelines for primary prevention of cardiovascular disease and stroke
Aha guidelines for primary prevention of cardiovascular disease and stroke
 
8 8 16_gerber_savagian_poster_final
8 8 16_gerber_savagian_poster_final8 8 16_gerber_savagian_poster_final
8 8 16_gerber_savagian_poster_final
 
Risk assessment for cardiovascular disease prevention
Risk assessment for cardiovascular disease preventionRisk assessment for cardiovascular disease prevention
Risk assessment for cardiovascular disease prevention
 
Consenso en prevención de enf cardiovascular en diabéticos
Consenso en   prevención de enf cardiovascular en diabéticosConsenso en   prevención de enf cardiovascular en diabéticos
Consenso en prevención de enf cardiovascular en diabéticos
 
Consenso en prevención de enf cardiovascular en diabéticos
Consenso en   prevención de enf cardiovascular en diabéticosConsenso en   prevención de enf cardiovascular en diabéticos
Consenso en prevención de enf cardiovascular en diabéticos
 
Consenso en prevención de enf cardiovascular en diabéticos
Consenso en   prevención de enf cardiovascular en diabéticosConsenso en   prevención de enf cardiovascular en diabéticos
Consenso en prevención de enf cardiovascular en diabéticos
 
Consenso en prevención de enf cardiovascular en diabéticos
Consenso en   prevención de enf cardiovascular en diabéticosConsenso en   prevención de enf cardiovascular en diabéticos
Consenso en prevención de enf cardiovascular en diabéticos
 
Consenso en prevención de enf cardiovascular en diabéticos
Consenso en   prevención de enf cardiovascular en diabéticosConsenso en   prevención de enf cardiovascular en diabéticos
Consenso en prevención de enf cardiovascular en diabéticos
 
Consenso en prevención de enf cardiovascular en diabéticos (1)
Consenso en   prevención de enf cardiovascular en diabéticos (1)Consenso en   prevención de enf cardiovascular en diabéticos (1)
Consenso en prevención de enf cardiovascular en diabéticos (1)
 
Consenso en prevención de enf cardiovascular en diabéticos
Consenso en   prevención de enf cardiovascular en diabéticosConsenso en   prevención de enf cardiovascular en diabéticos
Consenso en prevención de enf cardiovascular en diabéticos
 
Consenso en prevención de enf cardiovascular en diabéticos (1)
Consenso en   prevención de enf cardiovascular en diabéticos (1)Consenso en   prevención de enf cardiovascular en diabéticos (1)
Consenso en prevención de enf cardiovascular en diabéticos (1)
 
Consenso en prevención de enf cardiovascular en diabéticos
Consenso en   prevención de enf cardiovascular en diabéticosConsenso en   prevención de enf cardiovascular en diabéticos
Consenso en prevención de enf cardiovascular en diabéticos
 
2014 Report: Medicines in Development for Older Americans
2014 Report: Medicines in Development for Older Americans2014 Report: Medicines in Development for Older Americans
2014 Report: Medicines in Development for Older Americans
 
New Year, New You: Give 2012 a Heart Healthy Start!
New Year, New You: Give 2012 a Heart Healthy Start!New Year, New You: Give 2012 a Heart Healthy Start!
New Year, New You: Give 2012 a Heart Healthy Start!
 
259 crp as a risk factor
259 crp as a risk factor259 crp as a risk factor
259 crp as a risk factor
 
259 crp as a risk factor
259 crp as a risk factor259 crp as a risk factor
259 crp as a risk factor
 
Esv2n47
Esv2n47Esv2n47
Esv2n47
 
07 exemplo de metanálise
07   exemplo de metanálise07   exemplo de metanálise
07 exemplo de metanálise
 
Polypill for primary and secondary preventions of cardiovascular
Polypill for primary and secondary preventions of cardiovascularPolypill for primary and secondary preventions of cardiovascular
Polypill for primary and secondary preventions of cardiovascular
 

More from SHAPE Society

Acc vp-org 3-02 stone
Acc vp-org 3-02 stoneAcc vp-org 3-02 stone
Acc vp-org 3-02 stoneSHAPE Society
 
101205 shape aha 2005 f
101205 shape aha 2005 f101205 shape aha 2005 f
101205 shape aha 2005 fSHAPE Society
 
Acc presentation macrophage (1)
Acc presentation macrophage (1)Acc presentation macrophage (1)
Acc presentation macrophage (1)SHAPE Society
 
Acc presentation (1)
Acc presentation (1)Acc presentation (1)
Acc presentation (1)SHAPE Society
 
Acc presentation lipid coated(2)
Acc presentation lipid coated(2)Acc presentation lipid coated(2)
Acc presentation lipid coated(2)SHAPE Society
 
Acc 2002 microarray mehran for print
Acc 2002 microarray mehran for printAcc 2002 microarray mehran for print
Acc 2002 microarray mehran for printSHAPE Society
 
Acc2002 thermography
Acc2002 thermographyAcc2002 thermography
Acc2002 thermographySHAPE Society
 
#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st centurySHAPE Society
 
A20 is an atherosclerosis
A20 is an atherosclerosisA20 is an atherosclerosis
A20 is an atherosclerosisSHAPE Society
 
511 first steps towards understanding
511 first steps towards understanding511 first steps towards understanding
511 first steps towards understandingSHAPE Society
 
1688 azadpour 3 12 02
1688 azadpour 3 12 021688 azadpour 3 12 02
1688 azadpour 3 12 02SHAPE Society
 

More from SHAPE Society (20)

Barth imt
Barth imtBarth imt
Barth imt
 
Braunwald
BraunwaldBraunwald
Braunwald
 
Acc vp-org 3-02 stone
Acc vp-org 3-02 stoneAcc vp-org 3-02 stone
Acc vp-org 3-02 stone
 
101205 shape aha 2005 f
101205 shape aha 2005 f101205 shape aha 2005 f
101205 shape aha 2005 f
 
Acc v porg becker
Acc v porg beckerAcc v porg becker
Acc v porg becker
 
Acc 2005-1, v pl-vp
Acc 2005-1, v pl-vpAcc 2005-1, v pl-vp
Acc 2005-1, v pl-vp
 
Acc presentation macrophage (1)
Acc presentation macrophage (1)Acc presentation macrophage (1)
Acc presentation macrophage (1)
 
Acc v porg
Acc v porgAcc v porg
Acc v porg
 
Acc presentation (1)
Acc presentation (1)Acc presentation (1)
Acc presentation (1)
 
Acc presentation lipid coated(2)
Acc presentation lipid coated(2)Acc presentation lipid coated(2)
Acc presentation lipid coated(2)
 
Acc 2002 microarray mehran for print
Acc 2002 microarray mehran for printAcc 2002 microarray mehran for print
Acc 2002 microarray mehran for print
 
Acc booth inventory
Acc booth inventoryAcc booth inventory
Acc booth inventory
 
Acc 04 vuln pt
Acc 04 vuln ptAcc 04 vuln pt
Acc 04 vuln pt
 
Acc2002 thermography
Acc2002 thermographyAcc2002 thermography
Acc2002 thermography
 
A20 gene
A20 geneA20 gene
A20 gene
 
#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century
 
A20 is an atherosclerosis
A20 is an atherosclerosisA20 is an atherosclerosis
A20 is an atherosclerosis
 
511 first steps towards understanding
511 first steps towards understanding511 first steps towards understanding
511 first steps towards understanding
 
1688 azadpour 3 12 02
1688 azadpour 3 12 021688 azadpour 3 12 02
1688 azadpour 3 12 02
 
1031 talk2
1031 talk21031 talk2
1031 talk2
 

Recently uploaded

Ovarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptxOvarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptxSizan Thapa
 
ANATOMY OF CEREBELLUM With Clinical Anatomy.pptx
ANATOMY OF CEREBELLUM With Clinical Anatomy.pptxANATOMY OF CEREBELLUM With Clinical Anatomy.pptx
ANATOMY OF CEREBELLUM With Clinical Anatomy.pptxsiddharthroy26587
 
SGK PHÙ PHỔI CẤP ĐHYHN .pdf
SGK PHÙ PHỔI CẤP ĐHYHN                   .pdfSGK PHÙ PHỔI CẤP ĐHYHN                   .pdf
SGK PHÙ PHỔI CẤP ĐHYHN .pdfHongBiThi1
 
CANCER SeminarCancer Overview Type of Cancer.pptx
CANCER SeminarCancer Overview  Type of Cancer.pptxCANCER SeminarCancer Overview  Type of Cancer.pptx
CANCER SeminarCancer Overview Type of Cancer.pptxMrStavanUdayKadam
 
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptINTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptKavitha Krishnan
 
airway management recorded for S2.pptx
airway management  recorded  for S2.pptxairway management  recorded  for S2.pptx
airway management recorded for S2.pptxnakera38
 
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxsiddharthroy26587
 
TARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHUTARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHUKanhu Charan
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)chahattyagi200
 
Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)pranavguleria2
 
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTIONANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTIONojaswinihemane
 
Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Ahmad Thanin
 
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfSGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfHongBiThi1
 
Basic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisBasic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisAshishMaletha2
 
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...DUY NGUYEN PHUC
 
Explaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyExplaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyYves Sucaet
 
CELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCECELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCEShubhadip Ghosh
 
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfEMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfMayuriGamit2
 
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxNECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxSizan Thapa
 

Recently uploaded (20)

Ovarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptxOvarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptx
 
ANATOMY OF CEREBELLUM With Clinical Anatomy.pptx
ANATOMY OF CEREBELLUM With Clinical Anatomy.pptxANATOMY OF CEREBELLUM With Clinical Anatomy.pptx
ANATOMY OF CEREBELLUM With Clinical Anatomy.pptx
 
SGK PHÙ PHỔI CẤP ĐHYHN .pdf
SGK PHÙ PHỔI CẤP ĐHYHN                   .pdfSGK PHÙ PHỔI CẤP ĐHYHN                   .pdf
SGK PHÙ PHỔI CẤP ĐHYHN .pdf
 
CANCER SeminarCancer Overview Type of Cancer.pptx
CANCER SeminarCancer Overview  Type of Cancer.pptxCANCER SeminarCancer Overview  Type of Cancer.pptx
CANCER SeminarCancer Overview Type of Cancer.pptx
 
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptINTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
 
airway management recorded for S2.pptx
airway management  recorded  for S2.pptxairway management  recorded  for S2.pptx
airway management recorded for S2.pptx
 
Oral disorders .pptx
Oral disorders .pptxOral disorders .pptx
Oral disorders .pptx
 
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
 
TARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHUTARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHU
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)
 
Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)
 
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTIONANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
 
Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)
 
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfSGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
 
Basic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisBasic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth Analysis
 
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
 
Explaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyExplaining "pathology" in digital pathology
Explaining "pathology" in digital pathology
 
CELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCECELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCE
 
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfEMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
 
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxNECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
 

234 aha 2002 guideline, 1997 or 2002

  • 1. Editorial Slides VP Watch –July 24, 2002 - Volume 2, Issue 29 AHA 2002 Guideline; 1997 or 2002?
  • 2. Major Eras in Atherosclerosis Cholesterol Non-Lipid Risk Factors Immune Disorder 1950 1970 2002 (Inflammation Era) Diet Era 1 Era 2 Era 3
  • 3.  The landmark Seven Countries Study established the “diet-heart cholesterol theory”.  This classic diet-heart cholesterol theory is supported by results from ecological analyses, prospective studies, animal experiments, clinical observations, controlled trials, biochemical and nutritional studies.  Since 1968 extensive epidemiologic and clinical studies have identified several factors that increase the risk of CHD and MI, with effects not necessarily involving serum cholesterol and lipids.
  • 4.  Traditional Risk Factors (Era 1)  Sex  Age  Hypercholesterolemia  Smoking  Hypertension  Diabetes  Physical Activity  Family History
  • 5.  Non-Traditional Risk Factors (Era 2)  Fibrinogen  Homocysteine  White Blood Cell Count  LP(a)  ApoB/ApoA  Heart Rate  Socioeconomic Status  Stress  Type A Personality  Body Mass Index  …
  • 6.  Novel Risk Factors (Era 3)  CRP  IL-6  CD40/CD40L  Pathogen burden  HSP-60  …
  • 7. • “Risk Calculators” are only based on traditional risk factors: • Framingham Risk Assessment • Sheffield Risk Assessment • MONICA • Dundee • RisCard
  • 8.  The Framingham model uses age, sex, LDL or total cholesterol, HDL, systolic and diastolic blood pressure, the presence or absence of diabetes mellitus, and smoking status to predict the 10-year risk of CHD events. 10 • Sheffield table for primary prevention of coronary heart disease shows serum cholesterol concentration conferring an estimated risk of coronary events of 3.0% per year. 5
  • 9. • National Heart, Lung, and Blood Institute presented the risk assessment tool using information from the Framingham Heart Study to predict a person’s chance of having a heart attack in the next 10 years.  However, numerous studies have accumulated abundance of data indicating significance of non-traditional and emerging risk factors like CRP, fibrinogen, homocysteine, sLDL, and calcium score.
  • 10.  As reported in VP Watch of this week, Pearson et al. in 2002 update of AHA guidelines for primary prevention of cardiovascular disease and stroke integrated other guidelines and consensus statements developed since the initial Guide’s approval.11  This Guide is intended to assist primary care providers in their assessment, management, and follow-up of patients who may be at risk for but who have not yet manifested cardiovascular disease. 11
  • 11.  The aspirin guidelines recommended in this update agree with the Task Force Report in the use of aspirin in persons at high coronary and stroke risk but uses a 10% risk per 10 years rather than >6% risk over 10 years. 11  This change slightly restricts use of aspirin due to its potential adverse effects.
  • 12. Conclusion:  Despite the fast growing body of evidence for significance of non- traditional risk factors, the AHA 2002 Guideline calls screening tests for occult atherosclerosis based on non-traditional risk factors (CRP…) confined in the research arena, except ankle-brachial blood pressure index.
  • 13. Conclusion:  The Guideline also does not appreciate non-lipid lowering effects of statins and emphasizes that controversial interventions, such as very low-fat diets, dietary supplements, and potentially cardioprotective drugs other than aspirin require additional investigation in well- designed clinical trials in persons without established cardiovascular disease.
  • 14. Questions: • Should CRP be added to the package of screening tests for CVD primary prevention in asymptomatic populations? • How about for secondary prevention? • Should coronary calcium score be considered as an independent risk factor?
  • 15. Questions: • Is annual risk calculated based on population studies a reasonable basis for individual treatment? • Is 2% annual risk a proper cut point for intervention? • Do we need multiple risk cut points for different types of interventions e.g. life-style, conventional drug therapy, aggressive drug therapy, invasive treatment, etc? • Besides aspirin should we add other drug therapies (such as statins) to the primary intervention therapy?
  • 16. 1) Grundy SM, Balady GJ, Criqui MH, et al. Guide to primary prevention of cardiovascular diseases: a statement for healthcare professionals from the Task Force on Risk Reduction. American Heart Association Science Advisory and Coordinating Committee. Circulation. 1997; 95: 2329–2331 2) National Cholesterol Education Program: Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation.. 1994;89:1333-1445 3) Diane L. Tribble; Antioxidant Consumption and Risk of Coronary Heart Disease: Emphasis on Vitamin C, Vitamin E, and ß-Carotene : A Statement for Healthcare Professionals From the American Heart Association; Circulation 1999 99: 591 - 595. 4) Rosamond WD, Folsom AR, Chambless LE, Wang CH; ARIC Investigators. Atherosclerosis Risk in Communities.:Coronary heart disease trends in four United States communities. The Atherosclerosis Risk in Communities (ARIC) study 1987-1996. Int J Epidemiol. 2001 Oct;30 Suppl 1:S17-22. 5) Wallis EJ, Ramsay LE, Ul Haq I, Ghahramani P, Jackson PR, Rowland-Yeo K, Yeo WW: Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population. 6) Haq IU, Jackson PR, Yeo WW, Ramsay LE.: Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet 1995 Dec 2;346(8988):1467-71 7) Luc G, Bard JM, Ferrieres J, Evans A, Amouyel P, Arveiler D, Fruchart JC, Ducimetiere P.:Value of HDL Cholesterol, Apolipoprotein A- I, Lipoprotein A-I, and Lipoprotein A-I/A-II in Prediction of Coronary Heart Disease: The PRIME Study. Arterioscler Thromb Vasc Biol 2002 Jul 1;22(7):1155-61 8) Nallamothu BK, Fendrick AM, Omenn GS.Homocyst(e)ine and Coronary Heart Disease: Pharmacoeconomic Support for Interventions to Lower Hyperhomocyst(e)inaemia.Pharmacoeconomics 2002;20(7):429-42 9) Gerber Y, Goldbourt U, Cohen H, Harats D.:Association Between Serum Apolipoprotein C(II) Concentration and Coronary Heart Disease. Prev Med 2002 Jul;35(1):42-7 10) Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837- 47. 11) Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF Jr, Smith SC Jr, Stone NJ, Taubert KA. : AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. : Circulation. 2002 Jul 16;106(3):388-91. References